proportional hazards regression models were developed. We were able to balance 49 significantly different baseline characteristics using propensity score matching for 
Introduction

61
Statins, selective and competitive inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A ertapenem, doripenem, imipenem-cilastatin, or meropenem) or vancomycin for receiving daptomycin, we did not include patients with initial daptomycin therapy. We 118 excluded patients who died or were discharged on the day of culture or the day after 119 culture. We only evaluated the first admission within the study period after accounting 120 for all inclusion and exclusion criteria. 
Statin Use
123
All statin users were incident users not having used statins in the one year prior to 124 culture. The study was designed with this restriction criterion to avoid healthy user bias.
125
We defined incident pretreated statin users as those initiating a statin (i.e. atorvastatin, 
Statistical Analysis
149
We assessed baseline differences between statin exposure group and non-users using 150 a chi-square or Fisher's exact test for categorical variables and a t-test or non-
151
parametric Wilcoxon Rank Sum test for continuous variables. To generate propensity 8 scores (the predicted probability of statin use), we developed an unconditional logistic 153 regression model using a manual backward elimination approach (16, 17) . In the final 154 propensity score models, we checked for multicollinearity and goodness of fit, and ran 155 propensity score diagnostics (18) . We performed nearest neighbor propensity score 156 matching within 0.005 caliper (18) and reviewed subsequent covariate balance between 157 the matched groups (16, 17) .
159
To quantify the effect of statin therapy on clinical outcomes, we used Cox proportional 160 hazards regression models. Cox proportional hazards regression assumptions were 161 assessed, including proportionality (19) . These analyses were conducted separately for 162 each statin exposure group, in which separate propensity score models were built for 163 pretreated users with continuation, pretreated users without continuation, and de novo 164 users. Subsequent outcomes, compared to non-users, were assessed separately for 165 each of these statin exposure groups. A hazard ratio (HR) above 1 indicated an 166 increased probability of the outcome occurring sooner in the statin exposure group 167 compared to non-users. Number needed to treat was calculated from risk differences 168 among matched pairs. In sensitivity analyses, Cox models were adjusted for propensity 169 score quintiles, with quintile I serving as the reference, and weighted by the inverse 170 probability of treatment (20) . All analyses were performed using SAS (SAS Institute Inc.,
171
Cary, NC, Version 9.2).
Results
174
We identified 17,138 patients with S. aureus bacteremia who met our inclusion and 9 exclusion criteria (Figure 1 Time to event analyses comparing statin users to non-users (reference group) are 218 presented in Table 3 . No significant differences were observed between non-users and The 30-day mortality risk difference in pretreated statin users with continuation versus 242 non-users, was 99 per 1,000 patients (95% CI 10-189 per 1,000) and the number 243 needed to treat (NNT) was 10. For 14-day mortality, the risk difference was 78 per 12 1,000 patients (95% CI 8-148 per 1,000) and the NNT was 13. The 14-day and 30-day 245 survival probability curves for pretreated statin users with continuation versus non-users 246 can be found in Figure 2 . Recent statin initiation with continuation of statin therapy for at least 3 days after culture 250 was associated with a substantial protective effect on mortality among our large, 251 national, real-world cohort with S. aureus bacteremia. These findings were robust in our 252 primary analyses using propensity score matching, and in our sensitivity analyses using 253 propensity score quintile adjustment and inverse probability of treatment weighting. In sources, such a difference is difficult to ignore (26). In our study, catheter source was 311 similar between statin exposure groups and non-users (Table 1 those not continuing as a separate exposure group, both of which were compared to a 325 common reference group of non-users. Second, we included proxies for healthy 326 behaviors in our propensity score model, including use of preventative services (e.g. There are limitations in our study. First, although we employed propensity score 334 methods to address potential confounders of the association between use of statins and 335 the clinical outcomes, we were unable to control for unmeasured confounding. These methods allowed us to balance confounders of the exposure-outcome relationship that 337 were included in the propensity score, however it could not control for unbalanced 338 factors that were not measured in our study. Second, variations in point estimates were 339 observed with propensity score matching, adjustment, and inverse probability of 340 treatment weighting. Though propensity score matching produced the most 341 conservative estimates, it also resulted in the greatest balance between groups. Third, catheter in that field, we could not determine whether it was a catheter source. Lastly,
355
we did not assess outcomes for specific statins or doses, which is an important area of 356 inquiry as some data suggests added benefit of high potency or high dose statins (36, 2) Source of infection identified from ICD-9-CM diagnosis codes ±24 hours from culture collection.
* p<0.05 for pairwise comparison between statin exposure group and non-user group. 
